NASDAQ:RIGLRigel Pharmaceuticals Stock Price, Forecast & News

Rigel Pharmaceuticals' stock was trading at $1.81 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, RIGL stock has increased by 8.8% and is now trading at $1.97. View which stocks have been most impacted by Coronavirus.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rigel Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Rigel Pharmaceuticals.

Rigel Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Rigel Pharmaceuticals.

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) released its quarterly earnings data on Tuesday, May, 5th. The biotechnology company reported $0.13 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.13. The biotechnology company earned $55.76 million during the quarter, compared to analysts' expectations of $56.94 million. Rigel Pharmaceuticals had a negative net margin of 27.39% and a negative return on equity of 40.15%. View Rigel Pharmaceuticals' earnings history.

4 equities research analysts have issued 1 year price targets for Rigel Pharmaceuticals' stock. Their forecasts range from $6.00 to $8.00. On average, they expect Rigel Pharmaceuticals' stock price to reach $7.33 in the next year. This suggests a possible upside of 272.3% from the stock's current price. View analysts' price targets for Rigel Pharmaceuticals.

Media coverage about RIGL stock has been trending somewhat negative this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Rigel Pharmaceuticals earned a media sentiment score of -1.0 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news aboutRigel Pharmaceuticals.

Some companies that are related to Rigel Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Immunomedics (IMMU). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Rigel Pharmaceuticals investors own include Rite Aid (RAD), Geron (GERN), Terra Tech (TRTC), TherapeuticsMD (TXMD), Inovio Pharmaceuticals (INO), Synergy Pharmaceuticals (SGYP), Catalyst Pharmaceuticals (CPRX), Novavax (NVAX), Verastem (VSTM) and Aurora Cannabis (ACB).

Rigel Pharmaceuticals trades on the NASDAQ under the ticker symbol "RIGL."

Rigel Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Wellington Management Group LLP (9.32%), BlackRock Inc. (8.83%), Invesco Ltd. (2.97%), State Street Corp (2.11%), Morgan Stanley (1.49%) and Morgan Stanley (1.49%). Company insiders that own Rigel Pharmaceuticals stock include Anne-Marie Duliege, Dean L Schorno, Eldon C Mayer III, Nelson Cabatuan and Raul R Rodriguez. View institutional ownership trends for Rigel Pharmaceuticals.

RIGL stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Two Sigma Investments LP, Deutsche Bank AG, Squarepoint Ops LLC, Rhenman & Partners Asset Management AB, UBS Group AG, State Street Corp, and Parametric Portfolio Associates LLC. View insider buying and selling activity for Rigel Pharmaceuticals.

RIGL stock was purchased by a variety of institutional investors in the last quarter, including Sofinnova Investments Inc., Morgan Stanley, Morgan Stanley, Ikarian Capital LLC, Cadence Capital Management LLC, JPMorgan Chase & Co., Russell Investments Group Ltd., and Acadian Asset Management LLC. Company insiders that have bought Rigel Pharmaceuticals stock in the last two years include Dean L Schorno, Eldon C Mayer III, and Raul R Rodriguez. View insider buying and selling activity for Rigel Pharmaceuticals.

Shares of RIGL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of RIGL stock can currently be purchased for approximately $1.97.

Rigel Pharmaceuticals has a market capitalization of $332.08 million and generates $59.29 million in revenue each year. The biotechnology company earns $-66,890,000.00 in net income (profit) each year or ($0.40) on an earnings per share basis. Rigel Pharmaceuticals employs 158 workers across the globe.

The official website for Rigel Pharmaceuticals is www.rigel.com.

Rigel Pharmaceuticals' mailing address is 1180 VETERANS BOULEVARD, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-624-1100 or via email at [email protected]